March 16, 2026, Weather Update: Patient and staff safety remains our priority. If weather impacts your visit, please call to reschedule: 571‑350‑8400.
A monohydroxyl-substituted urea (hydroxycarbamate) antimetabolite. Hydroxyurea selectively inhibits ribonucleoside diphosphate reductase, an enzyme required to convert ribonucleoside diphosphates into deoxyribonucleoside diphosphates, thereby preventing cells from leaving the G1/S phase of the cell cycle. This agent also exhibits radiosensitizing activity by maintaining cells in the radiation-sensitive G1 phase and interfering with DNA repair. Check for active clinical trials using this agent. (NCI Thesaurus)